1. Home
  2. MBWM vs ANNX Comparison

MBWM vs ANNX Comparison

Compare MBWM & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercantile Bank Corporation

MBWM

Mercantile Bank Corporation

HOLD

Current Price

$59.75

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.25

Market Cap

873.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBWM
ANNX
Founded
1997
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
873.3M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
MBWM
ANNX
Price
$59.75
$5.25
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$55.67
$16.50
AVG Volume (30 Days)
94.5K
2.6M
Earning Date
04-21-2026
05-11-2026
Dividend Yield
3.08%
N/A
EPS Growth
10.95
N/A
EPS
2.82
N/A
Revenue
N/A
N/A
Revenue This Year
$20.28
N/A
Revenue Next Year
$4.67
$16,320.74
P/E Ratio
$21.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$42.75
$2.03
52 Week High
$62.39
$7.18

Technical Indicators

Market Signals
Indicator
MBWM
ANNX
Relative Strength Index (RSI) 51.56 50.26
Support Level $49.25 $5.10
Resistance Level $62.39 $5.63
Average True Range (ATR) 1.11 0.28
MACD -0.27 -0.01
Stochastic Oscillator 42.37 61.39

Price Performance

Historical Comparison
MBWM
ANNX

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: